Evidence map›Paper›PMID 38854935›Full record

ArticleTranslational lung cancer research2024

Outcomes of initial therapy for synchronous brain metastases from small cell lung cancer: a single-institution retrospective analysis.

Kevin V Chaung, Michael Z Kharouta, Andrew J Gross, Pingfu Fu, Mitchell Machtay, Tiffany R Hodges, Andrew E Sloan, Tithi Biswas, Afshin Dowlati, Serah Choi

Abstract read
In one paragraph

Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kevin V ChaungDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Michael Z KharoutaDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Andrew J GrossDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Pingfu FuDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.
Mitchell MachtayDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Tiffany R HodgesDepartment of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Andrew E SloanDepartment of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Tithi BiswasDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Afshin DowlatiDepartment of Medicine, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, OH, USA.
Serah ChoiDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.ORCID https://orcid.org/0000-0003-4968-2981

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell lung cancer (SCLC) has a propensity for brain metastases, which is associated with poor prognosis. We sought to determine predictors of overall survival (OS) and brain progression-free survival (bPFS) in SCLC patients with synchronous brain metastases at the time of initial SCLC diagnosis. A total of 107 SCLC patients with synchronous brain metastases treated at a single institution were included in this retrospective analysis. These patients had brain lesions present on initial staging imaging. Survival was estimated using the Kaplan-Meier method with log-rank test. Factors predictive of OS and bPFS were analyzed using Cox proportional hazards regression model. Median OS for the entire cohort was 9 months (interquartile range, 4.2-13.8 months) and median bPFS was 7.3 months (interquartile range, 3.5-11.1 months). OS was 30.3% at 1 year and 14.4% at 2 years, while bPFS was 22.0% at 1 year and 6.9% at 2 years. The median number of brain lesions at diagnosis was 3 (interquartile range, 2-8), and the median size of the largest metastasis was 2.0 cm (interquartile range, 1.0-3.3 cm). Increased number of brain lesions was significantly associated with decreased OS. Patients who received both chemotherapy and whole brain radiation therapy (WBRT) had improved OS (P=0.02) and bPFS (P=0.005) compared to those who had either chemotherapy or WBRT alone. There was no significant difference in OS or bPFS depending on the sequence of therapy or the dose of WBRT. Thirteen patients underwent upfront brain metastasis resection, which was associated with improved OS (P=0.02) but not bPFS (P=0.09) compared to those who did not have surgery. The combination of chemotherapy and WBRT was associated with improved OS and bPFS compared to either modality alone. Upfront brain metastasis resection was associated with improved OS but not bPFS compared to those who did not have surgery.

Indexed as

brain metastaseschemotherapycraniotomyradiation therapySmall cell lung cancer (SCLC)

Identifiers

PMID38854935
PMCPMC11157380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.